IBB ETF Rallies to All-Time High; Doubles S&P 500 Return

IBB ETF Rallies to All-Time High; Doubles S&P 500 Return Updated: 4/12/2013

The IBB (iShares NASDAQ Biotech, Expense Ratio 0.48%), the largest ETF in the biotech category, has surged this week to trade at a new all-time highs this morning. According to ETF Trends, IBB’s performance this year alone has more than doubled that of the S&P 500. The performance of the top holdings in IBB (REGN, GILD, AMGN and CELG) are leading the way for this ETF as the sector continues to do well. Read more from ETF Trends.

Nasdaq® and Nasdaq® are registered trademarks of The Nasdaq Group, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The Nasdaq Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

© 2015. The Nasdaq Group, Inc. All Rights Reserved.